Mandelia Ashish's Form 4 filing
Mersana Therapeutics, Inc. (MRSN) · filed Jan 19, 2022
- Accession no.
- 0001104659-22-005555
- Filed
- Jan 19, 2022
- Trade date
- Jan 14-18, 2022
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 4 derivative transactions. Open-market sales total $11.7K. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Mandelia AshishCIK 0001782805 | Officer (VP, Controller) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 14, 2022 | Common Stock | MOption exerciseDisposed | −833 | $0.00 | $0 | 1,666 | Direct | |
| Jan 14, 2022 | Common Stock | MOption exerciseDisposed | −4,520 | $0.00 | $0 | 13,557 | Direct | |
| Jan 14, 2022 | Common Stock | AGrant or awardAcquired | +28,700 | $0.00 | $0 | 28,700 | Direct | |
| Jan 14, 2022 | Common Stock | AGrant or awardAcquired | +19,133 | $0.00 | $0 | 19,133 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock upon vesting.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.83 to $5.92, inclusive. The reporting person undertakes to provide to Mersana Therapeutics, Inc., any security holder of Mersana Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
Referenced by the price of 1 transaction in Table I.